Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

10.0%

2 terminated/withdrawn out of 20 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

4 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

11 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

14(73.7%)

Phase 3

4(21.1%)

Phase 2

1(5.3%)

19Total

Phase 1(14)

Phase 3(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT07573215Unknown

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT07397338Phase 1Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Role: lead

NCT05557292Phase 1Terminated

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Role: collaborator

NCT07252232Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

NCT06625320Phase 3Active Not Recruiting

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

NCT06128551Phase 1Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Role: lead

NCT06922591Phase 1Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Role: collaborator

NCT05462717Phase 1Active Not Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Role: lead

NCT06445062Phase 1Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Role: lead

NCT07491445Phase 3Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT06881784Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Role: lead

NCT06162221Phase 1Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Role: lead

NCT07349537Phase 1Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Role: lead

NCT05054725Phase 2Completed

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Role: lead

NCT05379985Phase 1Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Role: lead

NCT06040541Phase 1Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Role: lead

NCT04418661Phase 1Terminated

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Role: collaborator

NCT04774952Phase 1Completed

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Role: lead

NCT03989115Phase 1Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Role: lead

NCT03634982Phase 1Unknown

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Role: lead

All 20 trials loaded